Opto Circuits is currently trading at Rs. 22.15, up by 0.55 points or 2.55% from its previous closing of Rs. 21.60 on the BSE.
The scrip opened at Rs. 21.95 and has touched a high and low of Rs. 22.65 and Rs. 21.10 respectively. So far 6,15,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 165.55 on 06-Jul-2012 and a 52 week low of Rs. 20.10 on 11-Jun-2013.
Last one week high and low of the scrip stood at Rs. 25.60 and Rs. 20.10 respectively. The current market cap of the company is Rs. 536.00 crore.
The promoters holding in the company stood at 28.17% while Institutions and Non-Institutions held 36.98% and 34.85% respectively.
Eurocor Gmbh, a group company of Opto Circuits (India), and its partner Micell Technologies, Inc. received CE (Conformite Europeenne) Mark approval for its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) introducing a thin-strut stent that features elimination of the coating from the stent in 45-60 days and the complete absorption of the polymer coating within 90 days.
The MiStent SES is unique in providing local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events. The MiStent SES approval is supported by in-depth clinical analysis from the DESSOLVE I and DESSOLVE II clinical trials. With this CE Mark approval, Micell is preparing to make the MiStent SES commercially available in Europe and other markets where CE Mark approval can expedite the registration process.
Opto Circuits India is a multinational medical device company headquartered out of Bengaluru, India. The company designs, develop, manufacture, market and distribute a range of medical products that are used by healthcare establishments in more than 150 countries.
| Company Name | CMP |
|---|---|
| Lenskart Solutions | 534.85 |
| Poly Medicure | 1468.25 |
| Laxmi Denta | 195.10 |
| Nureca Ltd. | 263.80 |
| Hemant Surgical Inds | 297.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: